For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Bio-Rad Laboratories, Inc. is among the ...

Nuvation Bio, Inc. (NYSE: NUVB) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price ...

That morning, Belite announced that its leading drug candidate, tinlarebant, met its primary endpoint in a phase 3 trial. The medicine was being tested to determine its efficacy in treating ...

On February 17, 2026, Knoll Capital Management disclosed a purchase of 473,591 shares of Nuvation Bio (NYSE:NUVB), an estimated $2.93 million trade based on quarterly average pricing. Nuvation Bio is ...

Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG) (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of ...